Related Experiment Video
Updated: May 13, 2026

Assessment of Child Anthropometry in a Large Epidemiologic Study
Published on: February 2, 2017
Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study
Brigitte M Sondermeijer1, S Matthijs Boekholdt, Jamal S Rana
1Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
Insights
The JUPITER criteria identified 10.1% of European adults for statin therapy, showing a higher risk of coronary heart disease (CHD) events. These individuals had significantly higher CHD event rates than those not meeting the criteria.
Area of Science:
- Cardiovascular disease prevention
- Epidemiology
- Clinical trial analysis
Background:
- The Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) criteria have been debated.
- Understanding the prevalence and risk profile of individuals meeting JUPITER criteria in contemporary European populations is crucial for guiding statin therapy decisions.
Purpose of the Study:
- To quantify the proportion of individuals meeting the JUPITER criteria in a European cohort.
- To determine the risk profile and coronary heart disease (CHD) event risk for JUPITER-eligible individuals during long-term follow-up.
- To compare the JUPITER criteria with existing risk assessment tools like SCORE and ATP III.
Main Methods:
- Analysis of the EPIC-Norfolk population cohort, including 25,639 participants aged 45-79 years.
- Long-term follow-up of 11.4 ± 2.8 years for coronary heart disease (CHD) events.
- Quantification of individuals meeting JUPITER criteria (low-density lipoprotein cholesterol-C <3.4 mmol/L and C-reactive protein ≥ 2 mg/L) and comparison with SCORE and ATP III criteria.
Main Results:
- Out of 8397 eligible individuals, 10.1% (846) met the JUPITER criteria.
- JUPITER-eligible individuals had a significantly higher 10-person-year event rate (14.6%) compared to those with LDL-C <3.4 mmol/L and C-reactive protein <2 mg (7.0%).
- The JUPITER criteria identified 18.1% and 18.9% of individuals not qualifying under SCORE or ATP III criteria, respectively.
Conclusions:
- Individuals meeting JUPITER criteria in this European cohort exhibited significantly higher coronary heart disease event rates.
- The JUPITER criteria identify a substantial proportion of the population for potential statin therapy who would not be candidates under SCORE or ATP III guidelines.
- These findings highlight the potential impact of JUPITER criteria on statin eligibility in primary prevention within European populations.
Aims:
Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) has raised several points of debate. We quantified the proportion of individuals meeting the JUPITER criteria, determined their risk profile, and their risk of coronary heart disease (CHD) events during a long-term follow-up in a contemporary European cohort.
Methods And Results:
A total of 25 639 participants aged between 45 and 79 years were followed for 11.4 ± 2.8 years in EPIC-Norfolk population cohort. A total of 8397 individuals with complete data available were considered potentially eligible for primary prevention. A total of 846 (10.1%) individuals fulfilled the JUPITER criteria [low-density lipoprotein cholesterol-C (LDL-C) <3.4 mmol/L/C-reactive protein ≥ 2 mg]. This group had a 10-person-year event rate of 14.6% compared with 7.0% for those with LDL-C <3.4 mmol/L/C-reactive protein <2 mg (P = 0.001); the corresponding adjusted hazard ratio for future CHD was 1.70 (95% CI: 1.31-2.21). The group fulfilling JUPITER criteria had significantly higher CHD risk compared with those with LDL-C ≥ 3.4 mmol/L and C-reactive protein <2 mg/L. Among individuals who did not qualify for statin therapy based on the Society of Cardiology Systematic COronary Risk Evaluation (SCORE) (n = 4652) or ATP III criteria (n = 4466), 18.1 and 18.9%, respectively, would have qualified using the JUPITER criteria.
Conclusion:
In this European cohort, JUPITER-eligible individuals had significantly higher event rates compared with those with LDL-C <3.4 mmol/L/C-reactive protein <2 mg and LDL-C ≥ 3.4 mmol/L/C-reactive protein <2 mg/L. Application of the JUPITER criteria qualified almost one-fifth of the population for statin therapy that otherwise would not have qualified based on SCORE or ATP III criteria.
Related Concept Videos
Bias in Epidemiological Studies
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health condition at a...
Confounding in Epidemiological Studies
Longitudinal Studies
Bioavailability Study Design: Healthy Subjects Versus Patients
Study Designs in Epidemiology
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and case-control studies.